投资要点康宁杰瑞:业内领先肿瘤药开发者,向双抗ADC华丽转身:康宁杰瑞是国内领先的生物制药公司。实控人徐霆博士持有公司33.01%股份。股权结构稳定,管理层经验丰富。目前已转型双抗ADC开发,构建了行业领先的糖基定点偶联技术,平台专利布局完善。工艺简单,偶联稳定。该平台获得国际药企ArriVent认可,与公司达成合作协议,共同应用该平台开发后续ADC产品。公司已开发新的ADC平台,能够同时偶联...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.